IL13RA2 and neoplasm: Studies utilizing single-cell RNA sequencing and spatial transcriptomics have shown that under the selective pressure of immunotherapies such as CAR T cells or monoclonal antibodies targeting EGFRvIII and IL13Rα2, tumor subclones can downregulate these target antigens.